SV293

SV293 is a novel small molecule dopamine D2 receptor-selective antagonist developed for the potential treatment of L-dopa-induced dyskinesia (LID) in Parkinson's Disease. It belongs to a class of substituted phenylpiperazine compounds and exhibits approximately 100-fold binding selectivity for the D2 receptor over the D3 receptor subtype. In preclinical studies using 6-hydroxydopamine (6-OHDA) unilaterally lesioned rat models, SV293 was characterized as a neutral antagonist with no intrinsic activity at D2 receptors. While it was evaluated for its ability to attenuate abnormal involuntary movements (AIMs), it showed only marginal efficacy (approximately 15% attenuation) and produced neuroleptic-like side effects, such as reduced mobility and flat posture, at therapeutic doses. Consequently, researchers concluded that SV293 and similar D2-selective antagonists were not viable candidates for further development as anti-dyskinetic agents compared to D3-selective compounds.